EUCTR2010-020319-34-AT进行中（未招募）不适用
SAFETY AND EFFICACY EVALUATION OF DOTAREM® IN MAGNETIC RESONANCE IMAGING (MRI) IN PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) LESIONS - SENTIO
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- GUERBET
- 入组人数
- 396
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •·Adult subject (having obtained legal majority age), and pediatric subjects (aged ³2 years) who will be enrolled only in Latin America and/or in the USA.
- •·Having known or highly suspected of having at least one lesion with a disruption of BBB and/or with abnormal vascularity (including tumoral, vascular, inflammatory or infectious diseases) in the brain (intracranial) and spine, who are scheduled to undergo a routine contrast-enhanced MRI of the CNS. This/these lesion(s) must have been detected by previous imaging evaluation. Any of the following modalities are accepted: nuclear medicine imaging, contrast-enhanced CT, CT, contrast-enhanced MRI, MRI, or x-ray angiography. The prior imaging evaluation should be obtained within 6 months before study MRI.
- •·If patients treated (either with radiation, surgery, biopsy, steroid, or other relevant treatments) between previous imaging evaluation and study MRI, there is still a high suspicion of remaining lesion(s) with disrupted BBB and/or with abnormal vascularity on the basis of available clinical information.
- •·Female of childbearing potential patients must have effective contraception (contraceptive pill or intra-uterine device) or be surgically sterilized or post-menopausal (minimum 12 months amenorrhea), or have a documented negative urine pregnancy test within 24 hours prior to study MRI.
- •·Having provided their written informed consent to participate in the study. For patients under legal majority age, the parent(s) or legal guardian of the patient must give their written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
- •·Adult subject (having obtained legal majority age), and pediatric subjects (aged ³2 years) who will be enrolled only in Latin America and/or in the USA.
- •·Having known or highly suspected of having at least one lesion with a disruption of BBB and/or with abnormal vascularity (including tumoral, vascular, inflammatory or infectious diseases) in the brain (intracranial) and spine, who are scheduled to undergo a routine contrast-enhanced MRI of the CNS. This/these lesion(s) must have been detected by previous imaging evaluation. Any of the following modalities are accepted: nuclear medicine imaging, contrast-enhanced CT, CT, contrast-enhanced MRI, MRI, or x-ray angiography. The prior imaging evaluation should be obtained within 6 months before study MRI.
- •·If patients treated (either with radiation, surgery, biopsy, steroid, or other relevant treatments) between previous imaging evaluation and study MRI, there is still a high suspicion of remaining lesion(s) with disrupted BBB and/or with abnormal vascularity on the basis of available clinical information.
- •·Female of childbearing potential patients must have effective contraception (contraceptive pill or intra-uterine device) or be surgically sterilized or post-menopausal (minimum 12 months amenorrhea), or have a documented negative urine pregnancy test within 24 hours prior to study MRI.
- •·Having provided their written informed consent to participate in the study. For patients under legal majority age, the parent(s) or legal guardian of the patient must give their written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •·Having acute or chronic Grade IV or V renal insufficiency, defined as an estimated GFR<30 mL/min/1.73m² within 7 days before study MRI.
- •·Known Class III/IV congestive heart failure according to the New York Heart Association classification;
- •·Suffering from long QT syndrome.
- •·Unstable health condition or circumstances (e.g. suffering from severe claustrophobia).
- •·Having any contraindications to MRI such as a pacemaker, magnetic material or any other conditions that would preclude proximity to a strong magnetic field.
- •·Known allergy to Gadolinium chelates.
- •·Having received any contrast agent within 3 days prior to study contrast administration, or is scheduled to receive any contrast agent within 24 hours after the study contrast administration.
- •·Pregnant, breastfeeding, or planning to become pregnant during the study.
- •·Previously participated in this study.
- •·Having participated within 30 days in another clinical study involving an investigational drug.
- •·Any condition which, based on the investigator's clinical judgement, would prevent the patient from completing all study assessments and visits (for example: mental or physical incapacity, language comprehension, geographical localisation, etc…).
- •·Inability or unwillingness to cooperate with the requirements of this study.
- •·Having acute or chronic Grade IV or V renal insufficiency, defined as an estimated GFR<30 mL/min/1.73m² within 7 days before study MRI.
- •·Known Class III/IV congestive heart failure according to the New York Heart Association classification;
- •·Suffering from long QT syndrome.
- •·Unstable health condition or circumstances (e.g. suffering from severe claustrophobia).
- •·Having any contraindications to MRI such as a pacemaker, magnetic material or any other conditions that would preclude proximity to a strong magnetic field.
- •·Known allergy to Gadolinium chelates.
- •·Having received any contrast agent within 3 days prior to study contrast administration, or is scheduled to receive any contrast agent within 24 hours after the study contrast administration.
- •·Pregnant, breastfeeding, or planning to become pregnant during the study.
- •·Previously participated in this study.
- •·Having participated within 30 days in another clinical study involving an investigational drug.
- •·Any condition which, based on the investigator's clinical judgement, would prevent the patient from completing all study assessments and visits (for example: mental or physical incapacity, language comprehension, geographical localisation, etc…).
- •·Inability or unwillingness to cooperate with the requirements of this study.
研究者
相似试验
进行中（未招募）
不适用
SAFETY AND EFFICACY EVALUATION OF DOTAREM® IN MAGNETIC RESONANCE IMAGING (MRI) IN PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) LESIONS - SENTIOPatient with Central Nervous System (CNS) LesionsMedDRA version: 12.1Level: SOCClassification code 10029205Term: Nervous system disordersEUCTR2010-020319-34-DEGUERBET396
进行中（未招募）
不适用
SAFETY AND EFFICACY EVALUATION OF DOTAREM® IN MAGNETICRESONANCE IMAGING (MRI) IN PATIENTS WITH CENTRAL NERVOUSSYSTEM (CNS) LESIONS (SENTIO Study) - SAFETY AND EFFICACY EVALUATION OF DOTAREM IN MRI OF CNS LESIONSCentral nervous (CNS) lesions (brain and spine lesions)MedDRA version: 12.1Level: SOCClassification code 10029205Term: NERVOUS SYSTEM DISORDERSEUCTR2010-020319-34-GBGuerbet Laboratories Ltd.396
进行中（未招募）
不适用
SAFETY AND EFFICACY EVALUATION OF DOTAREM IN MAGNETIC RESONANCE IMAGING (MRI) IN PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) LESIONS. - SENTIOPatients with CNS lesions (brain or spine).MedDRA version: 9.1Level: SOCClassification code 10029205EUCTR2010-020319-34-ITGUERBET396
已完成
3 期
Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) LesionsDiagnostic Self EvaluationCentral Nervous System DiseasesNCT01211873Guerbet416
进行中（未招募）
1 期
Study to evaluate the product flow, breakdown and elimination of DOTAREM from the blood and its safety and efficacy in children aged > 2 yearsPediatric subject aged <2 years (term newborn infants to toddlers 23 months of age inclusive) scheduled to undergo routine gadolinium-enhanced Magnetic Resonance Imaging of any body regionMedDRA version: 16.1Level: PTClassification code 10058644Term: Nuclear magnetic resonance imaging whole bodySystem Organ Class: 10022891 - InvestigationsEUCTR2013-003215-21-FRGUERBET50